Clinical commissioning policy: Rituximab for idiopathic membranous nephropathy (adults)

Document first published:: 21 October 2022
Page updated:: 11 November 2022
Topic:: Specialised commissioning
Publication type:: Policy or strategy

Rituximab is recommended to be available as a routine commissioning treatment option for idiopathic membranous nephropathy within the criteria set out in this document.

Document

Clinical commissioning policy Rituximab for idiopathic membranous nephropathy (adults)

Clinical commissioning policy Rituximab for idiopathic membranous nephropathy (adults)

PDF
147 KB

Document

Clinical panel report: Rituximab for idiopathic membranous nephropathy (adults)

Clinical panel report: Rituximab for idiopathic membranous nephropathy (adults)

PDF
33 KB

Document

Clinical priorities advisory group summary report: Rituximab for idiopathic membranous nephropathy (adults)

Clinical priorities advisory group summary report: Rituximab for idiopathic membranous nephropathy (adults)

PDF
192 KB

Document

Evidence review: Rituximab for idiopathic membranous nephropathy (adults)

Evidence review: Rituximab for idiopathic membranous nephropathy (adults)

PDF
673 KB

Document

Engagement report: Rituximab for idiopathic membranous nephropathy (adults)

Engagement report: Rituximab for idiopathic membranous nephropathy (adults)

PDF
82 KB

Document

Equality and Health Inequalities Impact Assessment (EHIA): Rituximab for idiopathic membranous nephropathy (adults)

Equality and Health Inequalities Impact Assessment (EHIA): Rituximab for idiopathic membranous nephropathy (adults)

PDF
92 KB